Nothing Special   »   [go: up one dir, main page]

PT1212417E - Promoção ou inibição de angiogénese e cardiovascularização - Google Patents

Promoção ou inibição de angiogénese e cardiovascularização Download PDF

Info

Publication number
PT1212417E
PT1212417E PT00939307T PT00939307T PT1212417E PT 1212417 E PT1212417 E PT 1212417E PT 00939307 T PT00939307 T PT 00939307T PT 00939307 T PT00939307 T PT 00939307T PT 1212417 E PT1212417 E PT 1212417E
Authority
PT
Portugal
Prior art keywords
polypeptides
present
compositions
cardiovascularization
disorders
Prior art date
Application number
PT00939307T
Other languages
English (en)
Inventor
Nicholas F Paoni
Paul J Godowski
Robert M Pitti
Napoleone Ferrara
Kevin P Baker
Hanspeter Gerber
Mary E Gerritsen
Audrey Goddard
Austin L Gurney
Colin K Watanabe
P Mickey Williams
William I Wood
Avi J Askenazi
Sophia S Kuo
Malanie R Mark
Scot A Marsters
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/en
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/en
Priority claimed from PCT/US1999/028409 external-priority patent/WO2000032778A2/en
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/en
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/en
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/en
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/en
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/en
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005004 external-priority patent/WO2000053757A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/006319 external-priority patent/WO2000053760A2/en
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT1212417E publication Critical patent/PT1212417E/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
PT00939307T 1999-06-02 2000-05-17 Promoção ou inibição de angiogénese e cardiovascularização PT1212417E (pt)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
PCT/US1999/012252 WO1999063088A2 (en) 1998-06-02 1999-06-02 Membrane-bound proteins and nucleic acids encoding the same
US14103799P 1999-06-23 1999-06-23
US14475899P 1999-07-20 1999-07-20
US14569899P 1999-07-26 1999-07-26
US14622299P 1999-07-28 1999-07-28
PCT/US1999/020111 WO2000012708A2 (en) 1998-09-01 1999-09-01 Further pro polypeptides and sequences thereof
PCT/US1999/028409 WO2000032778A2 (en) 1998-12-01 1999-11-30 Methods and compositions for inhibiting neoplastic cell growth
PCT/US1999/028313 WO2000032221A2 (en) 1998-12-01 1999-11-30 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US1999/028565 WO2000037638A2 (en) 1998-12-22 1999-12-02 Methods and compositions for inhibiting neoplastic cell growth
PCT/US1999/030095 WO2000037640A2 (en) 1998-12-22 1999-12-16 Compositions and methods for the treatment of tumor
PCT/US2000/000219 WO2000053753A2 (en) 1999-03-08 2000-01-05 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/000376 WO2000053755A2 (en) 1999-03-08 2000-01-06 Compositions and methods for the treatment of tumor
PCT/US2000/003565 WO2001053486A1 (en) 1999-03-08 2000-02-11 Compositions and methods for the treatment of tumor
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/005004 WO2000053757A2 (en) 1999-03-08 2000-02-24 Promotion or inhibition of angiogenesis and cardiovascularization
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
PCT/US2000/006319 WO2000053760A2 (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases
PCT/US2000/006884 WO2001005972A1 (en) 1999-07-20 2000-03-15 Compositions and methods for the treatment of immune related diseases
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
PCT/US2000/008439 WO2000073454A1 (en) 1999-06-02 2000-03-30 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
PT1212417E true PT1212417E (pt) 2008-07-29

Family

ID=39718295

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00939307T PT1212417E (pt) 1999-06-02 2000-05-17 Promoção ou inibição de angiogénese e cardiovascularização

Country Status (10)

Country Link
EP (1) EP1212417B1 (pt)
JP (2) JP4297317B2 (pt)
AT (1) ATE393825T1 (pt)
AU (1) AU5441200A (pt)
CA (1) CA2376116A1 (pt)
DE (1) DE60038740T2 (pt)
DK (1) DK1212417T3 (pt)
ES (1) ES2307515T3 (pt)
PT (1) PT1212417E (pt)
WO (1) WO2000073445A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO2000050620A2 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
DE10126371A1 (de) * 2001-05-30 2003-02-27 Medigene Ag Verfahren zur Identifizierung von Substanzen gegen Herzmuskelzellen-Hypertrophie
HRP20240623T1 (hr) * 2013-01-17 2024-08-02 Medizinische Hochschule Hannover Faktor 1 protein za uporabu u liječenju ili prevenciji bolesti
CN114507677B (zh) * 2022-02-16 2023-09-05 中国人民解放军空军军医大学 Ndufs1基因在治疗心梗后心衰中的应用和相关产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
DE69637734D1 (de) * 1996-08-16 2008-12-11 Human Genome Sciences Inc Menschliches alpha-endokin
JP4485049B2 (ja) * 1997-11-18 2010-06-16 ジェネンテック, インコーポレイテッド Dna19355ポリペプチドという腫瘍壊死因子相同体
CA2319236A1 (en) * 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same

Also Published As

Publication number Publication date
EP1212417B1 (en) 2008-04-30
ES2307515T3 (es) 2008-12-01
CA2376116A1 (en) 2000-12-07
JP2004506595A (ja) 2004-03-04
WO2000073445A3 (en) 2001-03-01
WO2000073445A2 (en) 2000-12-07
ATE393825T1 (de) 2008-05-15
EP1212417A2 (en) 2002-06-12
DE60038740D1 (de) 2008-06-12
JP4297317B2 (ja) 2009-07-15
DE60038740T2 (de) 2009-07-02
AU5441200A (en) 2000-12-18
DK1212417T3 (da) 2008-09-01
JP2009019032A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
IL202176A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2002008284A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A3 (en) Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2000053757A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
WO2000053752A3 (en) Promotion or inhibition of angiogenesis and cardiovascularization
HK1114636A1 (en) 1l-17 homologous polypeptides and therapeutic uses thereof
DK1032668T3 (da) Fibroblast vækstfaktor 19
WO2001055447A8 (en) Nucleic acids, proteins, and antibodies
WO2001055317A8 (en) Nucleic acids, proteins, and antibodies
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2001025433A3 (en) Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization
PT1212417E (pt) Promoção ou inibição de angiogénese e cardiovascularização
WO2001040464A8 (en) Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
EP1734051A3 (en) Composition and methods for the diagnosis of tumours
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
WO2001055449A8 (en) Nucleic acids, proteins, and antibodies
WO2001055313A8 (en) Nucleic acids, proteins, and antibodies